AstraZeneca (NYSE: AZN) updates voting rights and admits new shares

Rhea-AI Filing Summary

AstraZeneca PLC reported updated share capital and voting rights information. As at 31 March 2026, the company had 1,550,980,823 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, so total voting rights equal this amount.

The company also confirmed the admission to trading on the London Stock Exchange of 491 additional ordinary shares issued under its employee share schemes between 20 and 31 March 2026, under an existing block admission dated 29 January 2021. These new shares are fully fungible with existing ordinary shares.

Key Figures

Total voting rights: 1,550,980,823 shares Further securities admitted: 491 shares Nominal value per share: US$0.25 +2 more

5 metrics

Total voting rights 1,550,980,823 shares Ordinary shares with voting rights as at 31 March 2026

Further securities admitted 491 shares Additional ordinary shares issued under employee share schemes

Nominal value per share US$0.25 Ordinary shares of AstraZeneca PLC

Admission period 20–31 March 2026 Dates during which new employee scheme shares were issued

Block admission date 29 January 2021 Existing block admission under which new shares were admitted

Key Terms

Total Voting Rights, Disclosure and Transparency Rule 5.6.1, Public Offers and Admissions to Trading Regulations 2024 (POATRs), block admission, +1 more

5 terms

Total Voting Rights financial

"Total Voting Rights The following notification is made in accordance"

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Disclosure and Transparency Rule 5.6.1 regulatory

"in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1."

Public Offers and Admissions to Trading Regulations 2024 (POATRs) regulatory

"in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R."

block admission regulatory

"admitted under a block admission dated 29 January 2021"

employee share schemes financial

"Admission of shares under the Company's employee share schemes from 20 March 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights and Admission of Shares

1 April 2026

Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 March 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,980,823 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,980,823.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	491
d)	Total number of securities in issue following admission	1,550,980,823
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 20 March 2026 to 31 March 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 20 March 2026 up to 31 March 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 April 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) disclose in this April 2026 Form 6-K?

AstraZeneca reported updated share capital and voting rights and the admission of a small number of new shares. It confirmed the total voting rights figure and detailed the admission of additional ordinary shares issued under employee share schemes to the London Stock Exchange Main Market.

How many AstraZeneca (AZN) voting shares are in issue as of 31 March 2026?

As of 31 March 2026, AstraZeneca had 1,550,980,823 ordinary shares of US$0.25 in issue with voting rights. No shares are held in treasury, so the total number of voting rights in AstraZeneca PLC is also 1,550,980,823 for regulatory reporting purposes.

How many new AstraZeneca (AZN) shares were admitted to trading in March 2026?

AstraZeneca admitted 491 further ordinary shares of US$0.25 each to trading on the London Stock Exchange. These shares were issued between 20 March and 31 March 2026 under the company’s employee share schemes and fall under an existing block admission dated 29 January 2021.

Are AstraZeneca’s newly admitted shares different from existing ordinary shares?

The 491 newly admitted AstraZeneca shares are fully fungible with existing ordinary shares. They are ordinary shares of US$0.25 each and trade on the Main Market of the London Stock Exchange on the same terms as the company’s existing listed ordinary share capital.

How can AstraZeneca (AZN) shareholders use the total voting rights figure?

Shareholders may use the total of 1,550,980,823 voting rights as the denominator for regulatory calculations. This figure helps determine whether they must notify their interest, or any change in their interest, under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

What regulations govern AstraZeneca’s admission of further securities to trading?

The admission of further AstraZeneca shares is notified under The Public Offers and Admissions to Trading Regulations 2024 PRM 1.6.4R. The company also references the Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1 for its total voting rights announcement.